بحيرة مارتشيكا بالناظور.. تجربة رائدة في استزراع الطحالب
Schroder Investment Management Group reduced its holdings in Altria Group, Inc. (NYSE:MO – Free Report) by 12.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 331,536 shares of the company's stock after selling 45,469 shares during the period. Schroder Investment Management Group's holdings in Altria Group were worth $17,266,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Financial Life Planners bought a new stake in shares of Altria Group in the fourth quarter valued at about $25,000. VSM Wealth Advisory LLC bought a new stake in shares of Altria Group in the 4th quarter worth approximately $29,000. Marshall Investment Management LLC acquired a new stake in shares of Altria Group during the 4th quarter worth approximately $32,000. Promus Capital LLC bought a new stake in shares of Altria Group during the fourth quarter valued at approximately $33,000. Finally, Legacy Investment Solutions LLC acquired a new position in shares of Altria Group in the third quarter valued at $34,000. 57.41% of the stock is owned by institutional investors.
Shares of NYSE MO opened at $57.93 on Friday. Altria Group, Inc. has a 12-month low of $40.65 and a 12-month high of $60.18. The firm's 50-day simple moving average is $55.64 and its 200 day simple moving average is $53.75. The company has a market cap of $97.93 billion, a price-to-earnings ratio of 8.84, a price-to-earnings-growth ratio of 2.89 and a beta of 0.56.
Altria Group (NYSE:MO – Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.01. Altria Group had a negative return on equity of 258.72% and a net margin of 46.90%. On average, equities analysts expect that Altria Group, Inc. will post 5.32 earnings per share for the current year. Altria Group Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Tuesday, March 25th will be given a dividend of $1.02 per share. The ex-dividend date of this dividend is Tuesday, March 25th. This represents a $4.08 dividend on an annualized basis and a yield of 7.04%. Altria Group's payout ratio is presently 62.29%. Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the stock. Morgan Stanley decreased their price target on shares of Altria Group from $54.00 to $53.00 and set an 'equal weight' rating on the stock in a research note on Friday, January 31st. UBS Group upped their target price on shares of Altria Group from $42.00 to $46.00 and gave the company a 'sell' rating in a research note on Tuesday. Bank of America raised Altria Group from a 'neutral' rating to a 'buy' rating and increased their target price for the stock from $55.00 to $65.00 in a report on Friday, December 6th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Altria Group from a 'buy' rating to a 'hold' rating in a report on Tuesday. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of 'Hold' and a consensus price target of $54.00.
Get Our Latest Report on Altria Group About Altria Group
(Free Report)
Altria Group, Inc, through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand. Featured Articles
Want to see what other hedge funds are holding MO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altria Group, Inc. (NYSE:MO – Free Report).
companies with MarketBeat.com's FREE daily email newsletter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
2 minutes ago
- Glasgow Times
Finally, men have been banned from punching women in the face
It's hardly surprising, I think you'll agree, that it attracted my attention. Of all the memorable moments that came out of Paris 2024 last summer, perhaps the most, for all the wrong reasons, was Imane Khelif's boxing gold medal. Khelif's win turned out to be one of the most controversial victories in recent Olympic Games history, and became one of the most widely-covered and most commented-upon stories of Paris 2024. Khelif was fighting in the women's category but was, it was reported, biologically male. The allegations stemmed from the fact that the Algerian had been banned from competing in the women's event at the previous year's World Championships due to sex tests suggesting the presence of male chromosomes. Despite this, though, she had been cleared to fight at the Olympics due to the IOC going by whatever gender is on an athlete's passport. Khelif won gold in Paris, but her victory was entirely overshadowed by the controversy over her participation. Her second round opponent, Angela Carini of Italy, lasted 46 seconds of the fight before quitting, claiming post-fight that she had never been hit so hard in her life and she threw in the towel because she felt she had to 'preserve her life'. Khelif progressed through the Olympic boxing tournament and, with every victory, the outcry over her participation grew louder and louder. Imane Khelif became Olympic champion last summer (Image: Getty Images) Her critics said she was biologically male and so had no right to box in the women's tournament. She was, they claimed, putting females fighters' lives at risk and was making a mockery of the fairness of sport. Khelif's supporters asserted she had been born female and brought up as a female and so had every right to box as a woman. The Algerian threatened legal action against anyone who claimed, wrongfully she said, that she was male. What came out of Paris 2024 was that the evident absence of definitive rules surrounding any female athletes with gender questions hanging over them were far too loose. The question of who is male and who is female shouldn't, in theory, be particularly hard to answer. But those in charge of the sport displayed a complete dereliction of duty by ensuring that Khelif was engulfed in a storm about her gender. I assumed, as I think did many, that despite Khelif's protestations post-Paris that she would not just 'disappear', we wouldn't hear much from the Algerian for quite some time. How wrong I was. Khelif believed that, next week and less than 12 months after winning Olympic gold, she would be back in competitive action. The 26-year-old was scheduled to fight in the Eindhoven Box Cup - the women's event, of course - and as the tournament start date approached, the storm that engulfed her during the Olympics began to blow up once again. The confusion over Khelif's gender has not been helped by the opaque way the boxing authorities treated any information they'd gathered on her, as well as on Lin Yu-Ting, a fighter from Taiwan who also reportedly failed the same gender test as Khelif prior to Paris 2024, and who also went on to win Olympic gold last summer. The International Boxing Association, which ran the 2023 World Championships and ordered the disqualifications of the two fighters two years ago, said in a statement that the disqualifications came after 'the athletes did not undergo a testosterone examination but were subject to a separate and recognised test.' The specifics of the tests remain confidential but the IBA added that the results 'conclusively indicated that both athletes did not meet the required necessary eligibility criteria and were found to have competitive advantages over other female competitors.' That seems relatively conclusive to me, yet it seemed we were preparing to watch Khelif fight women once again. That she has been keen to fan the flames hasn't helped the situation. 'I see myself as a girl just like any other girl,' Khelif said in a recent interview. 'I was born a girl, raised as a girl, and have lived my entire life as one,' and a PR company enlisted by Khelif to work on her behalf reinforced this message, posting on Instagram earlier this week: 'When Imane lands a hit, enemy egos are sent straight to the graveyard.' It's hard to argue that this kind of inflammatory rhetoric is in the interest of anyone; not the other female fighters, not the sport and not Khelif herself. A last-minute intervention by the sport's recently installed global governing body, World Boxing, however, means Khelif will have to undergo sex-testing if she wants to compete next week, or in any subsequent tournament. Her withdrawal from next week's event in the Netherlands now seems inevitable, thus avoiding the inevitable backlash that would have exploded as soon as her first punch landed. The point that I made last summer still stands, though; by having such opaque and loose rules, the issue becomes about one individual, in this case Khelif. This is a wider issue than one single boxer but the lack of leadership remains the primary problem and leads to one, lone person becoming the centre of a story that is, in fact, about more than merely a single fighter. World Boxing's new ruling may have come late, but better late than never. And so, a year on from Paris 2024, we're finally, and thankfully, seeing men being stopped from punching women in the face. AND ANOTHER THING… The defeat of Josh Taylor by Ekow Essuman in Glasgow last weekend was both surprising and sad to watch. Taylor is one of Scotland's greatest-ever athletes - in becoming the undisputed light-welterweight champion of the world, Taylor joined a select group of fighters globally who have achieved such a feat. However, his defeat last weekend was his third loss in a row and such has been his inactivity, he's not won a competitive bout for over three years. Where Taylor goes now is interesting; does he persist with his comeback and fight what appears to be a losing battle to regain the form that saw him become the very best in the world? Taylor was defeated last weekend (Image: Steve Welsh/PA Wire) Or does he call it quits and hang up his gloves knowing he's in the record books as the most successful Scottish fighter ever? There's no easy answer for the 34-year-old and he's already said he's not going to make any rash decisions. Unless he truly believes he can return to the very top of boxing, I don't think we'll see him step into a ring again. If he retains the desire and the belief, though, there's every chance he will fight again. Either way, Taylor's record affords him as much time he needs to decide where his future lies. And whatever his decision, his record in the ring means he will go down as one of Scotland's true greats.
News24
3 minutes ago
- News24
Film boss quits after Gayton McKenzie allegedly intervenes over lavish spending
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
Economic Times
4 minutes ago
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
